SciVision Biotech Inc. announced that its Board of Directors approved the consolidated financial report for the first quarter of 2026 on May 14, 2026. For the reporting period from January 1 to March 31, 2026, the company recorded cumulative operating revenue of NT$205,322 thousand and an operating gross profit of NT$145,204 thousand. Net income attributable to owners of the parent was NT$21,956 thousand, resulting in a basic earnings per share of NT$0.29. Total assets at the end of the period were NT$2,751,444 thousand.